Skip to content

Construction of glioma multi-omics clinical cohort

Construction of glioma multi-omics clinical cohort

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074611
Enrollment
Unknown
Registered
2023-08-10
Start date
2023-08-31
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

Observation group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Part I Inclusion criteria: 1. The pathological diagnosis in our hospital was confirmed as high-grade glioma; 2. No suspected recurrent lesions were detected by enhanced MRI; 3. Complete concurrent chemoradiotherapy Part II Inclusion criteria: 1. Preoperative imaging suggested glioma

Exclusion criteria

Exclusion criteria: 1. The patient is underage, over 70 years old, or pregnant; 2. The patient refuses to join; 3. There are ferromagnetic implants or foreign bodies in the patient's body, claustrophobia or allergy to contrast media, etc., which cannot be subjected to nuclear magnetic examination; 4. The operation did not completely remove the original lesion; 5. Have received second-line treatment (including targeting, immunity, gamma knife, reradiotherapy, etc., excluding electric field); 6. KPS score below 60

Design outcomes

Primary

MeasureTime frame
Diagnosis of glioma;Efficacy of glioma;Prognosis of glioma;

Countries

China

Contacts

Public ContactLiu yanhui

Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu, China

liuyh@scu.edu.cn+86 189 8060 1509

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026